According to the NCI website, pacritinib is an orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V617F with potential antineoplastic activity.  Check for active clinical trials using this agent. (NCI Thesaurus)

More Information in English:

Link to Drug Information Portal, a service of the U.S. National Library of Medicine, National Institutes of Health

Link to National Cancer Institute

Wiki
Link to European Medicines Agency (EMEA)